Compass Therapeutics Inc (CMPX) — Titan Protect Analysis

CMPX

Compass Therapeutics Inc

Healthcare · ·

$2.04

Data: 2026-06-03

✓ ETHICAL PASS

NONE MOAT

LIMITED

Data Confidence: 0.0%

Key Metrics

How this company measures up on the fundamentals that matter

Market Cap

$375M

Total market value of the company

Trailing P/E

N/A

Forward P/E

-4.52

Based on estimated future earnings — lower means cheaper

Rev Growth

N/A

Year-over-year revenue change

Profit Margin

N/A

How much profit the company keeps from each dollar of revenue

ROE

-46.0%

Return on equity — how efficiently it uses shareholder money

Analyst Target

$7.00

+243% from current price — median analyst estimate

Recommendation

STRONG_BUY

Consensus view from 11 analysts covering this stock

About Compass Therapeutics Inc

Compass Therapeutics, Inc., a clinical-stage oncology-focused biopharmaceutical company, develops antibody-based therapeutics for the treatment of various human diseases in the United States. The company's lead product candidate, tovecimig, is a bispecific antibody that targets delta-like ligand 4 (DLL4) and vascular endothelial growth factor A (VEGF-A), which are critical to angiogenesis and tumor vascularization. It also develops CTX-471, an IgG4 monoclonal antibody that is an agonist of CD137

https://www.compasstherapeutics.com

Country: United States Employees: 39 Industry: Biotechnology

Ethical Screening

Five compliance checks based on AAOIFI standards — all must pass for ethical clearance

Business Activity

PASS

Core business does not involve prohibited activities

Debt Ratio

0.0% PENDING

Debt must be below 33% of total assets

Cash Ratio

0.0% PENDING

Interest-bearing cash below 33% of assets

Receivables

0.0% PENDING

Receivables below 49% of assets

Revenue Purity

0.0% PENDING

Non-compliant revenue below 5% — any excess requires purification

Quantitative Intelligence

Statistical analysis of price behaviour, risk, and market regime — independent of fundamental data

Regime

ACCUMULATION

Smart money appears to be building positions quietly

Sharpe Ratio

0.833

Good returns relative to risk taken

Kelly Fraction

0.0325

Modest edge detected — smaller position warranted

Calmar Ratio

0.382

Drawdown risk outweighs the returns — higher risk profile

Annual Return

28.7%

Historical annualised return based on price data

Max Drawdown

-75.0%

Largest peak-to-trough decline — the worst it has been

HMM State

BEAR

Statistical model detects bearish conditions

Days in State

How long the current regime has persisted — longer means more stable

Market Data

Trading characteristics and market positioning

Beta

0.67

Less volatile than the market — more defensive

52W High

$6.88

70% below the year high

52W Low

$1.61

27% above the year low

Avg Volume

7,472,011

Average daily shares traded — higher means easier to buy and sell

Short Ratio

2.1

Days it would take all short sellers to cover — higher means more crowded

Short % Float

N/A

Div Yield

N/A

Annual dividend as a percentage of the share price

EPS (TTM)

$-0.40

Earnings per share over the last 12 months

Financial Health

Balance sheet strength and cash generation — the foundation of long-term value

Debt/Equity

5.25

Heavy leverage — higher financial risk if revenues decline

Current Ratio

N/A

Quick Ratio

N/A

Like current ratio but excludes inventory — stricter test

Gross Margin

N/A

Revenue left after cost of goods — higher means pricing power

Operating Margin

N/A

Profit from core operations before interest and tax

Free Cash Flow

$-30,043,500

Negative — the business is spending more than it generates

Revenue (TTM)

N/A

Total revenue over the last 12 months

Net Income

$-68,173,000

Loss-making — spending exceeds revenue after all costs

Analyst Coverage

Analysts

Target High

$24.00

Target Median

$7.00

Target Low

$4.00

Explore the Ethical Screener View Track Record

Data sourced from public filings and market feeds. Not financial advice. Updated: 2026-06-03

Before you go